[1] |
World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization, 2020.
|
[2] |
World Health Organization. Repaid Communication: Key changes to the treatment of drug-resistant tuberculosis. Geneva: World Health Organization, 2019.
|
[3] |
中国防痨协会. 耐药结核病化学治疗指南(2019年). 北京: 人民卫生出版社, 2019.
|
[4] |
徐彩红, 赵雁林. 从《2020年全球结核病报告》看我国结核病防治工作. 中华传染病杂志, 2021, 39(7):392-397. doi: 10.3760/cma.j.cn311365-20210406-00117.
doi: 10.3760/cma.j.cn311365-20210406-00117
|
[5] |
Fregonese F, Ahuja SD, Akkerman OW, et al. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med, 2018, 6(4):265-275. doi: 10.1016/S2213-2600(18)30078-X.
doi: 10.1016/S2213-2600(18)30078-X
URL
|
[6] |
李琦, 李亮. 耐多药或利福平耐药结核病长程化疗方案与短程化疗方案的利与弊. 中华结核和呼吸杂志, 2019, 42(5):333-338. doi: 10.3760/cma.j.issn.1001-0939.2019.05.005.
doi: 10.3760/cma.j.issn.1001-0939.2019.05.005
|
[7] |
Van Deun A, Maug AK, Salim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med, 2010, 182(5):684-692. doi: 10.1164/rccm.201001-0077OC.
doi: 10.1164/rccm.201001-0077OC
URL
|
[8] |
Kuaban C, Noeske J, Rieder HL, et al. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis, 2015, 19(5):517-524. doi: 10.5588/ijtld.14.0535.
doi: 10.5588/ijtld.14.0535
pmid: 25868018
|
[9] |
Piubello A, Harouna SH, Souleymane MB, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis, 2014, 18(10):1188-1194. doi: 10.5588/ijtld.13.0075.
doi: 10.5588/ijtld.13.0075
pmid: 25216832
|
[10] |
World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis, 2016 Update. Geneva: World Health Organization, 2016.
|
[11] |
World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment: online annexes. Geneva: World Health Organization, 2020.
|
[12] |
Ionescu AM, Mpobela Agnarson A, Kambili C, et al. Bedaqui-line-versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res, 2018, 18(6):677-689. doi: 10.1080/14737167.2018.1507821.
doi: 10.1080/14737167.2018.1507821
URL
|
[13] |
Department of Health, Republic of South Africa. Management of rifampicin-resistant tuberculosis: a clinical reference guide. Pretoria: Department of Health, Republic of South Africa, 2019.
|
[14] |
Nimmo C, Millard J, Brien K, et al. Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients. Eur Respir J, 2020, 55(6):1902383. doi: 10.1183/13993003.02383-2019.
doi: 10.1183/13993003.02383-2019
URL
|
[15] |
Conradie F, Diacon AH, Ngubane N, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med, 2020, 382(10):893-902. doi: 10.1056/NEJMoa1901814.
doi: 10.1056/NEJMoa1901814
URL
|